Cerebral Small Vessel Diseases Clinical Trial
Official title:
The Effect of Anthocyanin Intake From Purple Sweet Potato on Vasomotor Reactivity of Intracranial Vessels in Cerebral Small Vessel Disease - a Study of Breath-Holding Index, Nitric Oxide, L-Arginine, Adiponectin, Cognitive and Gait
Cerebral small vessel disease (CSVD) is a major cause of disability, cognitive impairment, and functional loss in the elderly. CSVD occurs due to damage to arterioles, capillaries, and venules in the brain parenchyma, and can cause clinical and neuroimaging symptoms. CSVD also accounts for up to 25% of all ischemic stroke cases, and making it the second leading cause of death in the world after ischemic heart disease. Purple sweet potatoes, scientifically known as Ipomoea batatas (L.) Lam., contains of high anthocyanin specifically peonidin and cyanidin that has antioxidant, anti-inflammatory, and potentially phytoestrogenic activity. These anthocyanins have been linked to a reduced risk of obesity, diabetes, and high cholesterol. They also show potential in improving endothelial function, thereby enhancing blood vessel vasomotor function and potentially reducing the risk of cardiovascular diseases. Anthocyanins and their metabolites can cross the blood-brain barrier and affect signaling pathways, gene expression, and protein function at the molecular level. In addition to their ability to enhance vascular flow, anthocyanins can also help mitigate the risk factors associated with CSVD by counteracting oxidative stress in the body. These findings exploring the potential benefits of anthocyanins for individuals with CSVD by giving purple sweet potatoes extract comparing with placebo. The outcomes that will be assessed are vasomotor reactivity measured by Breath Holding Index in Transcranial Doppler, Nitric Oxide, L-Arginine and Adiponectin levels in blood, Cognitive Test and Gait.
Status | Not yet recruiting |
Enrollment | 90 |
Est. completion date | April 30, 2025 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 65 Years |
Eligibility | Inclusion Criteria: - CSVD patients aged 40-65 years. - CSVD patients have been diagnosed by MRI. - Willing to participate in the study and signed the consent letter after being given informed consent. - Have a Montreal Cognitive Assessment score of at least 26. - Able to walk independently with a motor score of at least 4, without proprioceptive disorders or neuropathy. Exclusion Criteria: - Closed temporal window on Transcranial Doppler examination - Acute phase of stroke - Hepatocellular injury - Chronic kidney disease - Intolerance to purple sweet potato - Aphasia - Neglected - Visual impairment. - Undergoing treatment with hormone replacement therapy (HRT), and corticosteroids. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Indonesia University | Fakultas Kedokteran Universitas Indonesia, Institut Pertanian Bogor, School of Science and technology, Kwansei Gakuin University, Universitas Padjadjaran |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Breath Holding Index | The assessment will be conducted by a Neurologist who has special expertise in neurosonology using Transcranial Doppler.
The outcome of this study is to find out the difference in scores from pre-intervention and post-intervention. |
Through study completion, an average of 1 year | |
Primary | Nitric Oxide | Nitric Oxide will be measured in plasma using Total Nitric Oxide and Nitrate/Nitrite Parameter Assay Kit.
The outcome of this study is to find out the difference in concentration from pre-intervention and post-intervention. |
Through study completion, an average of 1 year | |
Primary | L-Arginine | L-arginine will be measured in plasma using L- Arginine Assay Kit (Colorimetry) The outcome of this study is to find out the difference in concentration from pre-intervention and post-intervention. | Through study completion, an average of 1 year | |
Primary | Adiponectin | Adiponectin will be measured in serum using Human Total Adiponectin/Acrp30 Quantikine ELISA Kit The outcome of this study is to find out the difference in concentration from pre-intervention and post-intervention. | Through study completion, an average of 1 year | |
Primary | Cognitive | The subjects will take a cognitive function test, namely Trail Making Test (TMT) A and Trail Making Test (TMT) B.
The TMT-A test consists of combining numbers from 1 to 25, while the TMT-B test consists of alternating numbers and letters. TMT A and B are scored based on how long it takes to complete the test. This study is to find out the difference in scores from pre-intervention and post-intervention. |
Through study completion, an average of 1 year | |
Primary | Gait | The Timed Up and Go (TUG) test examination included assessment of the patient's balance, gait speed, and functional capacity. The TUG test assessment consisted of the subject standing up from a chair (chair height 46 cm, chair armrest height 65 cm), walking 3 meters, turning around, and walking 3-meters back to the chair and sitting down, at a spontaneous gait speed. The time taken to perform the test was measured using a stopwatch. The time recorded on the STANDARDIZED stopwatch was the TUG score. | Through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04041349 -
Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease
|
Phase 4 | |
Recruiting |
NCT04109963 -
Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment
|
Phase 2 | |
Not yet recruiting |
NCT06416371 -
Retinal Vessel Leakage in Cerebral Small Vessel Disease
|
||
Not yet recruiting |
NCT05967728 -
Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care
|
Phase 2 | |
Completed |
NCT05714813 -
Circuit Training and Retina
|
N/A | |
Not yet recruiting |
NCT06077305 -
A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke
|
||
Not yet recruiting |
NCT06061692 -
Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study(TOPS-CSVD)
|
Phase 4 | |
Recruiting |
NCT04962295 -
China Imaging-based Biobank of Cerebral Small Vessal Diseases
|
||
Completed |
NCT02801032 -
Effect of Tadalafil on Cerebral Large Arteries in Stroke
|
Phase 2 | |
Not yet recruiting |
NCT05594966 -
Neuroimaging Combining Biomarkers for Identifying Long-term Cognitive Dysfunction and Delirium
|
||
Terminated |
NCT02890888 -
Effect of Hyperbaric Oxygen on Functional Connectivity in Patients With Cerebral Small Vessel Disease
|
N/A | |
Recruiting |
NCT04318119 -
Cerebral Small Vessel Disease Registry Study
|
||
Recruiting |
NCT03906123 -
The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia
|
N/A | |
Recruiting |
NCT05306834 -
Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease
|
N/A | |
Not yet recruiting |
NCT05583266 -
Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM)
|
Phase 4 | |
Recruiting |
NCT05173896 -
Improving Cerebral Blood Flow and Cognition in Patients With Cerebral Small Vessel Disease. The ETLAS-2 Trial
|
Phase 2 | |
Recruiting |
NCT01819441 -
Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients
|
Phase 4 | |
Recruiting |
NCT01688505 -
Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function
|
N/A | |
Recruiting |
NCT04330222 -
Cambridge 7 Tesla Cerebral Small Vessel Disease Study
|
||
Recruiting |
NCT04298866 -
White Matter Hyperintensities Subtypes in Cerebral Small Vessel Disease : 7 Tesla Ultra-high Resolution Imaging MRI
|
N/A |